{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-25-000004","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.859422+00:00","generated_at":"2026-05-28T03:10:09.761917+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Akebia guides cash runway of at least two years, funding Vafseo launch and pipeline","bullets":["Expects existing cash and cash from ops to fund current plan for at least two years.","Funding supports U.S. Vafseo launch and planned pipeline advancement.","CEO John Butler presenting at 43rd Annual J.P. Morgan Healthcare Conference on Jan 16, 2025.","Cautionary language regarding potential need for additional funding if plan changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-25-000004","json":"https://secwatch.observer/filing/0001517022-25-000004.json","markdown":"https://secwatch.observer/filing/0001517022-25-000004.md","text":"https://secwatch.observer/filing/0001517022-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000004/0001517022-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000004/akba-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:10:09.761917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}